Programme(s) to which this project applies:
|☒ MPhil/PhD||☑ MRes[Med]||☒ URIS|
Objectives and Significance:
Malignant glioma is the commonest form of primary malignant brain tumours in adults. It is characterised by tumour invasiveness, rapid recurrence and a very poor patient prognosis. Temozolomide (TMZ) is an effective chemotherapeutic agent for glioma but drug-resistance is common and accounts for the majority of treatment failures. A better understanding of the underlying molecular mechanisms is crucial. The present project aims at identifying relevant molecular candidates that can be exploited as potential biomarkers and therapeutic targets. Several potential targets and treatments may be examined in the Supervisor ‘s laboratory. The ultimate goal is to translate laboratory findings into the effective treatment of malignant glioma with de novo or acquired TMZ-resistance.
Research Plan and Methodology:
For more information or to express interest for this project, please email the supervisor or the specified contact point in the project description. Interested candidates are advised to enclose with your email:
Information on the research programme, funding support and admission documentations could be referenced online at the Research Postgraduate Admissions website. General admission enquiries should be directed to firstname.lastname@example.org.
HKUMed MBBS students interested in the Master of Research in Medicine (MRes[Med]) programme may visit the programme website for more information.
HKUMed UG students interested in the Undergraduate Research Internship Scheme (URIS) may visit the scheme’s website for more information.